369 related articles for article (PubMed ID: 15855226)
1. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
Kalofonos HP; Aravantinos G; Kosmidis P; Papakostas P; Economopoulos T; Dimopoulos M; Skarlos D; Bamias A; Pectasides D; Chalkidou S; Karina M; Koutras A; Samantas E; Bacoyiannis C; Samelis GF; Basdanis G; Kalfarentzos F; Fountzilas G
Ann Oncol; 2005 Jun; 16(6):869-77. PubMed ID: 15855226
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Kalofonos HP; Papakostas P; Makatsoris T; Papamichael D; Vourli G; Xanthakis I; Aravantinos G; Papadimitriou C; Pentheroudakis G; Varthalitis I; Samelis G; Syrigos KN; Xiros N; Stavropoulos M; Kosmidis P; Christodoulou C; Linardou H; Skondra M; Pectasides D; Economopoulos T; Fountzilas G
Anticancer Res; 2010 Oct; 30(10):4325-33. PubMed ID: 21036759
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
[TBL] [Abstract][Full Text] [Related]
4. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
Zhuang L; Bai J; Huang H; Tang C; Yang J; Zhou B; Gong Y; Duanmu Z; Chen J
Oncol Res; 2010; 18(9):437-44. PubMed ID: 20524401
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
7. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
[TBL] [Abstract][Full Text] [Related]
8. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Tournigand C; André T; Achille E; Lledo G; Flesh M; Mery-Mignard D; Quinaux E; Couteau C; Buyse M; Ganem G; Landi B; Colin P; Louvet C; de Gramont A
J Clin Oncol; 2004 Jan; 22(2):229-37. PubMed ID: 14657227
[TBL] [Abstract][Full Text] [Related]
9. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.
Comella P; Massidda B; Filippelli G; Palmeri S; Natale D; Farris A; De Vita F; Buzzi F; Tafuto S; Maiorino L; Mancarella S; Leo S; Lorusso V; De Lucia L; Roselli M
Ann Oncol; 2005 Jun; 16(6):878-86. PubMed ID: 15837702
[TBL] [Abstract][Full Text] [Related]
13. FDA drug approval summaries: oxaliplatin.
Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
[TBL] [Abstract][Full Text] [Related]
14. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Rougier P; Lepille D; Bennouna J; Marre A; Ducreux M; Mignot L; Hua A; Méry-Mignard D
Ann Oncol; 2002 Oct; 13(10):1558-67. PubMed ID: 12377643
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
[TBL] [Abstract][Full Text] [Related]
16. A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer.
Ramanathan RK; Bjarnason GA; Bernard SA; Desimone P; Braich T; Evars JP; Hrushesky WJ; Jolivet J
Clin Colorectal Cancer; 2008 Mar; 7(2):134-9. PubMed ID: 18501073
[TBL] [Abstract][Full Text] [Related]
17. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Cunningham D; Sirohi B; Pluzanska A; Utracka-Hutka B; Zaluski J; Glynne-Jones R; Koralewski P; Bridgewater J; Mainwaring P; Wasan H; Wang JY; Szczylik C; Clingan P; Chan RT; Tabah-Fisch I; Cassidy J
Ann Oncol; 2009 Feb; 20(2):244-50. PubMed ID: 18854549
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
20. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
